Alpine Immune Sciences, Inc. (ALPN)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Alpine Immune Sciences, Inc. (ALPN) with AI Score 57/100 (Hold). Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing protein-based immunotherapies. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Alpine Immune Sciences, Inc. (ALPN) Healthcare & Pipeline Overview
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company specializing in protein-based immunotherapies for cancer and autoimmune diseases, leveraging its unique platform to develop novel treatments like ALPN-101, ALPN-202, and ALPN-303, positioning it within the competitive biotechnology landscape.
Investment Thesis
Alpine Immune Sciences presents a notable research candidate within the biotechnology sector. The company's innovative pipeline, particularly ALPN-101, ALPN-202, and ALPN-303, targets significant unmet needs in autoimmune diseases and cancer. The collaboration with AbbVie for ALPN-101 validates the potential of Alpine's platform and provides financial resources for further development. Key value drivers include successful clinical trial outcomes for its lead programs, potential regulatory approvals, and expansion of its pipeline through internal research and strategic partnerships. A potential risk lies in the inherent uncertainty of clinical development and regulatory approval processes. The company's negative profit margin of -54.7% indicates that it is not currently profitable and relies on external funding or partnership revenue. Continued progress in clinical trials and strategic collaborations are essential for realizing the company's long-term value.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $4.46B reflects investor confidence in Alpine's pipeline and technology.
- P/E ratio of -100.94 indicates the company is currently not profitable, typical for clinical-stage biopharmaceutical companies.
- Gross Margin of -37.4% reflects high R&D expenses associated with drug development.
- Beta of 0.97 suggests the stock's volatility is similar to the overall market.
- Collaboration agreement with AbbVie for ALPN-101 provides financial support and validation of the program's potential.
Competitors & Peers
Strengths
- Innovative protein engineering platform.
- Promising pipeline of immunotherapies.
- Strategic collaborations with major pharmaceutical companies.
- Experienced management team.
Weaknesses
- Clinical-stage company with no currently approved products.
- High R&D expenses and negative profitability.
- Reliance on external funding and partnerships.
- Pipeline concentration on a few key programs.
Catalysts
- Upcoming: Clinical trial data releases for ALPN-101 in autoimmune diseases.
- Upcoming: Clinical trial data releases for ALPN-202 in cancer immunotherapy.
- Ongoing: Enrollment and progression of patients in ongoing clinical trials.
- Ongoing: Potential for new strategic partnerships and collaborations.
Risks
- Potential: Clinical trial failures or regulatory setbacks.
- Potential: Competition from other biotechnology and pharmaceutical companies.
- Potential: Intellectual property challenges.
- Ongoing: High R&D expenses and reliance on external funding.
Growth Opportunities
- Expansion of ALPN-101 into new autoimmune indications: ALPN-101, currently in development for autoimmune and inflammatory diseases, has the potential to be expanded into additional indications such as lupus, rheumatoid arthritis, and inflammatory bowel disease. The market for autoimmune disease therapies is estimated to reach $150 billion by 2028, offering a substantial growth opportunity for Alpine. Successful clinical trials and regulatory approvals in these new indications could significantly increase the value of ALPN-101.
- Advancement of ALPN-202 in cancer immunotherapy: ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, represents a novel approach to cancer immunotherapy. The market for cancer immunotherapies is projected to reach $75 billion by 2027. Alpine can explore ALPN-202 in combination with other cancer therapies, such as checkpoint inhibitors and chemotherapy, to enhance its efficacy and broaden its applicability across different cancer types.
- Development of ALPN-303 for B cell-mediated diseases: ALPN-303, a dual B cell cytokine antagonist, targets B cell-mediated inflammatory and autoimmune diseases. The market for B cell therapies is growing rapidly, driven by the increasing prevalence of autoimmune diseases and the development of more targeted therapies. Alpine can leverage its expertise in protein engineering to develop ALPN-303 as a differentiated therapy with improved efficacy and safety profiles.
- Strategic partnerships and collaborations: Alpine can pursue additional strategic partnerships and collaborations with pharmaceutical companies and academic institutions to accelerate the development and commercialization of its pipeline. These partnerships can provide access to additional funding, expertise, and resources, as well as expand Alpine's reach into new markets and therapeutic areas. The collaboration with AbbVie for ALPN-101 serves as a successful example of this strategy.
- Expansion into new therapeutic areas: Alpine can leverage its protein engineering platform to expand into new therapeutic areas beyond cancer and autoimmune diseases. This could include developing immunotherapies for infectious diseases, metabolic disorders, and other diseases with significant unmet needs. By diversifying its pipeline, Alpine can reduce its reliance on any single therapeutic area and create new growth opportunities.
Opportunities
- Expansion into new therapeutic areas and indications.
- Advancement of pipeline programs through clinical development.
- Further strategic partnerships and collaborations.
- Potential for regulatory approvals and commercialization of its products.
Threats
- Competition from other biotechnology and pharmaceutical companies.
- Clinical trial failures and regulatory setbacks.
- Intellectual property challenges.
- Changes in the regulatory landscape.
Competitive Advantages
- Proprietary protein engineering platform for developing novel immunotherapies.
- Strong intellectual property protection for its drug candidates.
- Strategic collaborations with leading pharmaceutical companies.
- Experienced management team with expertise in drug development and commercialization.
About ALPN
Alpine Immune Sciences, Inc., founded in 2007 and headquartered in Seattle, Washington, is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative protein-based immunotherapies. The company's primary focus is on addressing significant unmet needs in cancer, autoimmune/inflammatory disorders, and other diseases. Alpine's scientific approach centers around modulating the immune system to achieve therapeutic benefits. Their product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist designed for the treatment of autoimmune and inflammatory diseases. ALPN-202 is a conditional CD28 costimulator and dual checkpoint inhibitor being developed for cancer therapy. ALPN-303, a dual B cell cytokine antagonist, targets B cell-mediated inflammatory and autoimmune diseases. These programs represent Alpine's commitment to developing differentiated therapies with the potential to improve patient outcomes. Alpine has established strategic collaborations to advance its pipeline, including a partnership with AbbVie Ireland Unlimited Company for the development of ALPN-101 and a collaboration with Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. The company's research and development efforts are geared towards creating novel immunotherapies that can offer improved efficacy and safety profiles compared to existing treatments.
What They Do
- Develop protein-based immunotherapies.
- Target cancer, autoimmune/inflammatory disorders, and other diseases.
- Create inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonists.
- Develop conditional CD28 costimulators and dual checkpoint inhibitors.
- Engineer dual B cell cytokine antagonists.
- Collaborate with other companies to develop next-generation SPEAR T cell products.
Business Model
- Develop novel immunotherapies through internal research and development.
- Out-license or co-develop its drug candidates with pharmaceutical partners.
- Generate revenue through upfront payments, milestone payments, and royalties from partnered programs.
Industry Context
Alpine Immune Sciences operates within the competitive biotechnology industry, which is characterized by rapid innovation, high R&D costs, and stringent regulatory requirements. The market for immunotherapies is experiencing significant growth, driven by advances in understanding the immune system and the increasing prevalence of cancer and autoimmune diseases. Key trends include the development of personalized therapies, the use of combination therapies, and the exploration of new immune targets. Alpine competes with other biotechnology companies developing immunotherapies, as well as established pharmaceutical companies with existing products in these therapeutic areas. The company's success depends on its ability to develop differentiated therapies with improved efficacy and safety profiles.
Key Customers
- Pharmaceutical companies seeking to expand their immunotherapy portfolios.
- Patients suffering from cancer and autoimmune/inflammatory disorders.
- Healthcare providers who prescribe and administer immunotherapies.
Financials
Chart & Info
Alpine Immune Sciences, Inc. (ALPN) stock price: Price data unavailable
Latest News
-
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
benzinga · Apr 11, 2024
-
Earnings Scheduled For March 23, 2023
benzinga · Mar 23, 2023
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Oct 24, 2022
-
Earnings Scheduled For March 18, 2021
· Mar 18, 2021
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALPN.
Price Targets
Wall Street price target analysis for ALPN.
MoonshotScore
What does this score mean?
The MoonshotScore rates ALPN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Earnings Scheduled For March 23, 2023
Stocks That Hit 52-Week Lows On Monday
Earnings Scheduled For March 18, 2021
Leadership: Mitchell H. Gold
CEO
Mitchell H. Gold serves as the CEO of Alpine Immune Sciences, bringing extensive experience in the biopharmaceutical industry. His career includes leadership roles at several biotechnology companies, where he oversaw drug development, clinical trials, and regulatory approvals. He has a strong background in immunology and oncology, with a focus on developing innovative therapies for unmet medical needs. Gold's expertise spans from early-stage research to late-stage clinical development and commercialization. He is known for his strategic vision and ability to build successful teams.
Track Record: Under Mitchell H. Gold's leadership, Alpine Immune Sciences has advanced its pipeline of immunotherapies, including ALPN-101, ALPN-202, and ALPN-303, through clinical development. He has secured strategic collaborations with major pharmaceutical companies, such as AbbVie, to support the development and commercialization of Alpine's products. Gold has also overseen the expansion of Alpine's protein engineering platform and the development of new drug candidates.
What Investors Ask About Alpine Immune Sciences, Inc. (ALPN)
What does Alpine Immune Sciences, Inc. do?
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company that specializes in developing protein-based immunotherapies. Their focus is on creating innovative treatments for cancer, autoimmune disorders, and inflammatory diseases by modulating the immune system. The company's pipeline includes ALPN-101, ALPN-202, and ALPN-303, each designed to target specific pathways involved in immune regulation. Alpine aims to develop therapies that offer improved efficacy and safety profiles compared to existing treatments, addressing unmet medical needs in these therapeutic areas. They operate by researching, developing, and partnering to bring novel immunotherapies to market.
What do analysts say about ALPN stock?
Analyst consensus on Alpine Immune Sciences is pending further analysis. However, key valuation metrics to consider include the company's market capitalization of $4.46B and its negative P/E ratio of -100.94, reflecting its current lack of profitability. Growth considerations revolve around the successful advancement of its pipeline programs through clinical trials and potential regulatory approvals. The collaboration with AbbVie for ALPN-101 is a positive sign, but the company's high R&D expenses and reliance on external funding remain factors to watch.
What are the main risks for ALPN?
The main risks for Alpine Immune Sciences include the inherent uncertainties of clinical development, such as the potential for clinical trial failures or regulatory setbacks. Competition from other biotechnology and pharmaceutical companies developing similar therapies also poses a risk. Intellectual property challenges and the need to secure and maintain patent protection are critical considerations. Additionally, the company's high R&D expenses and reliance on external funding make it vulnerable to changes in the financial markets and investor sentiment. These factors could impact Alpine's ability to advance its pipeline and achieve its long-term goals.
What are the key factors to evaluate for ALPN?
Alpine Immune Sciences, Inc. (ALPN) currently holds an AI score of 57/100, indicating moderate score. Key strength: Innovative protein engineering platform.. Primary risk to monitor: Potential: Clinical trial failures or regulatory setbacks.. This is not financial advice.
How frequently does ALPN data refresh on this page?
ALPN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ALPN's recent stock price performance?
Recent price movement in Alpine Immune Sciences, Inc. (ALPN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative protein engineering platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ALPN overvalued or undervalued right now?
Determining whether Alpine Immune Sciences, Inc. (ALPN) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ALPN?
Before investing in Alpine Immune Sciences, Inc. (ALPN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending for ALPN.